Concepedia

John McNulty

JM

Statistics

Publications

8

Citations

449

H-Index

8

Active since

1998

Affiliations

AstraZeneca (United States)(Current)

University of Connecticut

AstraZeneca (United Kingdom)

United States Food and Drug Administration

Takeda (United States)

John McNulty is an author at AstraZeneca (United States) specializing in pharmacology, antibacterial pharmacology, and antibiotic resistance.

Publications per year

1998–2019

8

Publications

8

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

Gregory S. Basarab, Günther Kern, John McNulty et al. · Scientific Reports · 2015 · 104 citations · Full text

, , +16

Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II with Reduced p<i>K</i><sub>a</sub>: Antibacterial Agents with an Improved Safety Profile

Folkert Reck, Richard A. Alm, Patrick Brassil et al. · Journal of Medicinal Chemistry · 2012 · 92 citations · Full text

, , +17

Replication Inhibition and Miscoding Properties of DNA Templates Containing a Site-Specific <i>cis</i>-Thymine Glycol or Urea Residue

John McNulty, Bozidar Jerkovic, Philip H. Bolton et al. · Chemical Research in Toxicology · 1998 · 91 citations

, , +17

Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization

Gregory S. Basarab, Patrick Brassil, P. Doig et al. · Journal of Medicinal Chemistry · 2014 · 56 citations · Full text

, , +16

Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice

Kanita Salic, Robert Kleemann, Cynthia E. Wilkins-Port et al. · PLoS ONE · 2019 · 40 citations · Full text

, , +17

1–5 of 8